Safety of intravenous iron formulations: facts and folklore - Wikidata - awgldk - TriplyDB

Safety of intravenous iron formulations: facts and folklore

Safety of intravenous iron formulations: facts and folklore

http://www.wikidata.org/entity/Q26853397

about

Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century Is Correction of Iron Deficiency a New Addition to the Treatment of the Heart Failure?The Italian Regulatory Guidelines for the implementation of Patient Blood Management."Simplified International Recommendations for the Implementation of Patient Blood Management" (SIR4PBM)To the rescue: the role of intravenous iron in the management of severe anaemia in the peri-partum setting.Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults.A fast-track anaemia clinic in the Emergency Department: feasibility and efficacy of intravenous iron administration for treating sub-acute iron deficiency anaemia Management of Iron Deficiency Anemia.The Important Role for Intravenous Iron in Perioperative Patient Blood Management in Major Abdominal Surgery: A Randomized Controlled Trial.Safety of intravenous iron use in chronic kidney disease.The Labile Side of Iron Supplementation in CKD Diagnosis, Treatment, and Prevention of Hemodialysis Emergencies.Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA).Reply to "Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185."Intravenous iron and safety: is the end of the debate on the horizon?Iron therapy in heart failure patients without anaemia: possible implications for chronic kidney disease patients.Treating iron deficiency in patients with gastrointestinal disease: Risk of re-attendance in secondary care.Iron: a double-edged sword.Treating iron deficiency.Assessing the costs and benefits of perioperative iron deficiency anemia management with ferric carboxymaltose in Germany.

P2860

Q26752664-60443A7B-94D1-43F2-A15B-7B15E460E1EE Q27012538-AE0BA1E3-E4FC-45CD-BA36-D90EACFFA7B8 Q33852520-0404F08F-DB97-408B-9C2A-34209C0E6EFE Q34681138-B14A377A-6558-4A9F-83AA-5E30F3E4478E Q35049204-0B0B4792-982B-44BC-8E89-7DCE11B4E7BC Q36515685-4FF7DF0A-D463-46EC-AAE0-3448E359918D Q36660755-602F48A8-9449-4DC2-B4E1-AA11C3859781 Q36812538-2C669604-F56F-4ECE-82DF-9E0CE10C0F97 Q36992752-26D641C7-82FA-4845-BBD8-82C14623056A Q37320585-699FC2DC-7604-4D44-91A6-82A47CFD037C Q38496987-7A57A820-DF27-48BD-B9F9-C70CB13C554F Q38796784-2531DBA8-6C5C-4A44-9FE8-CD9BDFBACBA7 Q41847007-942CC7EF-F150-4D26-8E89-774541ABCE7B Q41914964-2677C812-DC38-4772-AEFD-20336B44A278 Q42750147-46F58D3E-DB47-40FC-8835-E0E7F674D303 Q47141724-EE20FB00-0853-49C9-B645-C07F582CBDEC Q47157022-E2042BEE-A994-49DF-8D75-E7C0265E077B Q49860166-B5790287-5639-4840-9757-E124825AA9C0 Q54839570-B459C7DE-B67D-484C-A2E5-EB26D6D2710A Q55485778-DEA7AA90-1452-432B-A1A6-EC40C12797FB

P2860

Safety of intravenous iron formulations: facts and folklore

http://www.wikidata.org/entity/Q26853397

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Safety of intravenous iron formulations: facts and folklore

@ast

Safety of intravenous iron formulations: facts and folklore

@en

Safety of intravenous iron formulations: facts and folklore

@nl

type

label

Safety of intravenous iron formulations: facts and folklore

@ast

Safety of intravenous iron formulations: facts and folklore

@en

Safety of intravenous iron formulations: facts and folklore

@nl

prefLabel

Safety of intravenous iron formulations: facts and folklore

@ast

Safety of intravenous iron formulations: facts and folklore

@en

Safety of intravenous iron formulations: facts and folklore

@nl

P1433

Q26853397-04F61952-7979-479B-9618-92690ED81753

P1476

Q26853397-E14D6454-1BB4-4202-9747-9D8C58BEE02D

P2093

Q26853397-73BA04C5-AD84-408A-B9AC-F842AFC4041F

Q26853397-AF134072-101A-4A93-927A-7CF6F2A76023

P2860

Q26853397-06C9A3CA-FF71-41AF-B0C4-1FA639F72D16

Q26853397-114668FC-7B52-4D1E-8114-700A8859327D

Q26853397-131EC7F6-C75B-49CF-B62E-F3EF7A67DADA

Q26853397-16B91147-72E3-4227-B3F3-1476A8570F51

Q26853397-182B6AA9-19C0-4E39-AB6E-DE3642407AE3

Q26853397-1F89F3E2-0622-44C4-AA0C-F83A988A188C

Q26853397-26DAB627-B5EF-445D-A520-269660EBD197

Q26853397-2FFD15E3-7361-41A1-8ADA-1740F144D8E2

Q26853397-38D49F4C-FC03-47AB-89F9-148A93285943

Q26853397-45D9C03F-C711-4213-BA16-E7B74DDB6B77

P304

Q26853397-040B9728-8628-4BBB-8335-50C94B56A865

P31

Q26853397-C2EE83D4-BF09-4E99-A226-08159D1ECADE

P3181

Q26853397-1461C9AA-9970-4AFF-A477-9BECFB5625F8

P356

Q26853397-EEBCD273-24EE-4E9D-B74D-BEC68C86ADDA

P407

Q26853397-35C977F4-5875-43A8-8ACB-16D40509D41F

P433

Q26853397-A474249B-3742-43EE-84C8-3585392C5117

P478

Q26853397-58158DE4-4CB4-4BB7-820A-D7BC5036DA9A

P577

Q26853397-02D104CE-B0C0-43B1-907D-25F83C3F59CC

P698

Q26853397-C5E8688D-9F93-4EAF-89D1-46073F336A66

P932

Q26853397-1A1D9071-EA05-492F-9D81-B231E02903F4

P3181

P356

P1433

Blood transfusion = Trasfusione del sangue

P1476

Safety of intravenous iron formulations: facts and folklore

@en

P2093

Auerbach M

http://www.w3.org/2001/XMLSchema#string

Macdougall IC

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials

On the relative safety of parenteral iron formulations

A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications

Very-short-term perioperative intravenous iron administration and postoperative outcome in major orthopedic surgery: a pooled analysis of observational data from 2547 patients.

Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.

Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.

A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients.

Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients

Intravenous iron: from anathema to standard of care.

Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia.

P304

296-300

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2251152

http://www.w3.org/2001/XMLSchema#string

P356

10.2450/2014.0094-14

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25074787

http://www.w3.org/2001/XMLSchema#string

P932

4111808

http://www.w3.org/2001/XMLSchema#string